54gene's African-genomics bet: $45M raised, 100,000-sample biobank, then 2023 wind-down

54gene was a Lagos-based genomics company that built a biobank of African DNA samples and ran sequencing and diagnostics services, aiming to supply pharma with data from the world's most genetically diverse continent.

African genetic data would become a commercially valuable asset for global pharma: build Africa's largest biobank and sell drug-makers access to its diversity.

US$45M+ across three rounds ($4.5M seed in 2019, $15M Series A led by Adjuvant in 2020, $25M Series B led by Cathay AfricInvest in 2021)

Founded in early 2019 in Lagos by Dr. Abasi Ene-Obong, a geneticist and former pharma consultant, 54gene set out to build the continent's largest biobank. It joined Y Combinator and Google for Startups, raised a then-record $4.5M seed for Nigerian healthtech, and closed a $15M Series A with Adjuvant Capital in April 2020.

A $25M Series B in September 2021 funded a whole-genome sequencing lab and a diagnostics arm, Seven River Labs. During COVID 54gene scaled Nigeria's daily testing from about 100 to over 1,000 samples and booked $20M+ in revenue; its biobank reached 100,000 Nigerians across 300 ethnic groups and its valuation peaked around $170M. When COVID demand collapsed, a planned $100M Series C failed, 95 staff were laid off, and the CEO changed twice within a year.

In July 2023 54gene began winding down — "could not continue to operate financially," said then-CEO Ron Chiarello — and by September its website was gone. In August 2025 a Lagos Federal High Court blocked the sale of its assets, including biodata of 100,000 Nigerians priced at $3M, while founder Ene-Obong alleged the lead investors engineered the collapse; the case was pending.

Africa's genetic diversity was genuinely underrepresented in research, so the gap 54gene attacked was real and measurable.

COVID diagnostics brought revenue and national relevance, but that revenue was cyclical — not a recurring data business — and masked weak product-market fit.

Sequencing equipment and biobanking are capital-intensive, so when post-COVID revenue fell and the next round failed, the fixed costs were untenable.

Founder-investor conflict — two CEO changes in a year and a reported valuation cut from $170M to $50M — destroyed the confidence needed to raise or sell.

A data asset is worth only what a customer will pay today: 54gene proved demand for African genomics, but the value stayed a promise once COVID testing revenue vanished.

As of September 2025 54gene was defunct and its assets were frozen in litigation. Winding down began in July 2023; by September its website was gone. In August 2025 a Lagos Federal High Court injunction blocked the sale of its biobank — biodata of 100,000 Nigerians priced at $3M — in proceedings brought by founder Abasi Ene-Obong, who alleged Cathay AfricInvest and Adjuvant engineered the collapse of a company once valued near $170M. The investors said they acted in the company's best interests; the case awaited judgment, and Ene-Obong had moved on to a new venture, Syndicate Bio.